 AIM ImmunoTech Inc NYSE:AIM announced positive data from a Phase 12 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer. The study has been published in the American Association for Cancer Research publication, Clinical Cancer Research under the title, Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity. 